STALICLA secures $17.4 Million in Series B Round
STALICLA’s Precision Neuro Advancements propelled by $17.4 Million in Series B Funding Geneva, Switzerland, January 16th, 2024 – STALICLA SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million. Led by SPRIM Global Investments Pte, … Read more